HomeCompareRECEF vs JNJ

RECEF vs JNJ: Dividend Comparison 2026

RECEF yields 909.09% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RECEF wins by $8252648.18M in total portfolio value
10 years
RECEF
RECEF
● Live price
909.09%
Share price
$0.22
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$8252648.21M
Annual income
$6,784,560,004,057.53
Full RECEF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — RECEF vs JNJ

📍 RECEF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRECEFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RECEF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RECEF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RECEF
Annual income on $10K today (after 15% tax)
$77,272.73/yr
After 10yr DRIP, annual income (after tax)
$5,766,876,003,448.90/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, RECEF beats the other by $5,766,875,999,462.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RECEF + JNJ for your $10,000?

RECEF: 50%JNJ: 50%
100% JNJ50/50100% RECEF
Portfolio after 10yr
$4126324.12M
Annual income
$3,392,280,004,373.47/yr
Blended yield
82.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

RECEF
No analyst data
Altman Z
-148.3
Piotroski
1/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RECEF buys
0
JNJ buys
0
No recent congressional trades found for RECEF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRECEFJNJ
Forward yield909.09%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$8252648.21M$30.3K
Annual income after 10y$6,784,560,004,057.53$4,689.40
Total dividends collected$8138900.96M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RECEF vs JNJ ($10,000, DRIP)

YearRECEF PortfolioRECEF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$101,609$90,909.09$10,592$272.30+$91.0KRECEF
2$972,011$863,288.79$11,289$357.73+$960.7KRECEF
3$8,758,157$7,718,105.75$12,123$472.89+$8.75MRECEF
4$74,364,546$64,993,317.91$13,141$629.86+$74.35MRECEF
5$595,318,755$515,748,691.06$14,408$846.81+$595.30MRECEF
6$4,495,664,203$3,858,673,134.79$16,021$1,151.60+$4495.65MRECEF
7$32,043,550,537$27,233,189,840.42$18,122$1,588.22+$32043.53MRECEF
8$215,696,715,677$181,410,116,602.38$20,930$2,228.20+$215696.69MRECEF
9$1,372,045,052,584$1,141,249,566,809.58$24,792$3,191.91+$1372045.03MRECEF
10$8,252,648,210,323$6,784,560,004,057.53$30,274$4,689.40+$8252648.18MRECEF

RECEF vs JNJ: Complete Analysis 2026

RECEFStock

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.

Full RECEF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this RECEF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RECEF vs SCHDRECEF vs JEPIRECEF vs ORECEF vs KORECEF vs MAINRECEF vs ABBVRECEF vs MRKRECEF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.